Loading…
Loading…
QRON (Qrons Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Cognitive performance and functional wellness brand expands its focus across mental readiness, active lifestyles and everyday performance LOS ANGELES, Aug. 18, 2026 /PRNewswire/ -- First Person (OTCMarkets: QRON), a cognitive performance and functional wellness company and a wholly owned subsidiary of Qrons, Inc., today announced the next phase of its growth following early consumer momentum for Think Fast™, its premium functional coffee powered by proprietary Crystallized Lion's Mane technology. Think Fast™ has quickly become one of First Person's fastest-growing products, driven by consumers incorporating it into routines centered on focus, productivity, and mental performance.
NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University.
NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company's strides in dealing with infectious disease and sepsis with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death.
NEW YORK, NY / ACCESSWIRE / August 14, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the filing on August 9, of a United States Provisional Patent Application entitled Tellurium Compositions and Techniques For Use Therewith. This filing is in furtherance of its Neuronal and Infectious Disease treatments development, including sepsis.
NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Qrons Inc. (OTCQB:QRON) announced today the signing of a License Agreement Term Sheet effective July 17, 2023 with Professors Benjamin Sredni & Michael Albeck of Bar Ilan University in Israel for an exclusive world-wide, perpetual license of their IP in Tellurium based compounds. The IP will be used together Qrons' IP created by Dr. Ido Merfeld, Qrons co-founder as part of a new research program to experiment and commercialize the therapeutic effect of certain Tellurium based compounds on antibiotic resistance bacterial infections, Sepsis and Traumatic Brain Injuries.